# SPI-1005 for the Treatment of Meniere's Disease (Open Label)

> **NCT06859788** · PHASE3 · RECRUITING · sponsor: **Sound Pharmaceuticals, Incorporated** · enrollment: 200 (estimated)

## Conditions studied

- Meniere's Disease
- Ménière's Disease

## Interventions

- **DRUG:** Ebselen

## Key facts

- **NCT ID:** NCT06859788
- **Lead sponsor:** Sound Pharmaceuticals, Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-29
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06859788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06859788, "SPI-1005 for the Treatment of Meniere's Disease (Open Label)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06859788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*